Skip to content
Open·Synced from source July 16, 2026

NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)

National Institutes of Health

Apply at National Institutes of Health

Free. Verify your email, then we send one reminder only.

Posted
Dec 17, 2025
Closes
May 8, 2028 (in 662 days)
Last verified
Jul 16, 2026

Classification and identifiers

Solicitation number
PAR-25-447
Assistance listing (CFDA)
93.837

Amount

Amount not published by the funder

Who can apply

State governmentsLocal governmentsCounty governmentsSchool districtsNonprofitsSpecial districts

State government agencies, Local government agencies, and Nonprofits, including small and volunteer-run organizations can all apply here. Check the eligibility details below to see if your organization fits.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

About this opportunity

This Notice of Funding Opportunity (NOFO) invites applications to use NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders. No funding will be provided under this NOFO. The genomic data and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBIs BioData Catalyst (BDC). The overall goal is to move from simply cataloguing genetic associations to understanding how genetic factors contribute to HLBS diseases at the molecular and cellular levels. This transformation will help move TOPMed from genetic Map to ...

Refine this search